Mitinab 400mg Tablet

About

Mitinab 400mg Tablet is a highly specialized targeted therapy medication, categorized as a potent tyrosine kinase inhibitor (TKI). Its sophisticated mechanism of action involves the selective and precise blockade of the activity of specific tyrosine kinases, which are critical enzymes that play pivotal roles in regulating cellular growth, proliferation, and survival, particularly within certain types of malignant cells. By effectively inhibiting these aberrant signaling pathways that drive cancer progression, Mitinab actively works to prevent the uncontrolled growth and division of cancerous cells, ultimately leading to significant disease control or even regression. This medication is typically indicated for the treatment of specific cancers that are characterized by the overexpression or activating mutations of these particular target kinases. Given its potent and highly specific pharmacological action, treatment with Mitinab necessitates rigorous and careful monitoring for both therapeutic efficacy and the potential for significant adverse effects, which can include hematological and organ toxicities.

Uses

• Treatment of chronic myeloid leukemia (CML).
• Management of gastrointestinal stromal tumors (GIST).
• Therapy for certain types of acute lymphoblastic leukemia (ALL).
• Treatment of other specific solid tumors or hematologic malignancies.

Directions For Use

Take one tablet orally with a meal and a large glass of water, exactly as prescribed by your oncologist. Do not crush, chew, or break the tablet.

Benefits

• Targets specific cancer cells, minimizing harm to healthy cells.
• Effective in controlling disease progression.
• Can induce remission in certain cancers.
• Improves patient survival rates.
• Offers a non-chemotherapeutic treatment option.
• Provides a more tolerable side effect profile compared to traditional chemotherapy for some patients.

Side Effects

• Nausea and vomiting
• Diarrhea
• Fluid retention (edema)
• Muscle cramps
• Fatigue
• Skin rash
• Headache
• Abdominal pain
• Myelosuppression (low blood counts)
• Liver enzyme elevation
• Periorbital edema
• Weight gain

Safety Measures

• Alcohol - Alcohol consumption should be avoided or strictly limited while taking Mitinab 400mg Tablet, as it may exacerbate liver toxicity and other gastrointestinal side effects.
• Pregnancy - Mitinab 400mg Tablet is contraindicated in pregnancy due to potential fetal harm. Effective contraception must be used by women of childbearing potential during treatment and for a period after.
• Breastfeeding - It is not known if Mitinab 400mg Tablet is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment.
• Liver - Mitinab 400mg Tablet can cause hepatotoxicity. Liver function tests should be monitored regularly, and dose adjustments or interruption may be necessary in patients with liver impairment.
• Kidney - Caution is advised in patients with kidney impairment. Renal function should be monitored, and dose adjustments of Mitinab 400mg Tablet may be required based on the severity of renal dysfunction.
• Lung - Rare but serious pulmonary adverse events, including interstitial lung disease, have been reported with TKIs. Patients with pre-existing lung conditions should be monitored closely.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.